Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Multiple myeloma (MM) patients with smoldering (S) disease are defined by a lack of CRAB/SLiM criteria but may transform into disease requiring treatment. The International Myeloma Working Group risk stratification model for SMM uses serum M-protein, serum-free light chain ratio, and bone marrow plasma cell percentage. We investigated whether baseline serum B-cell maturation antigen (sBCMA) levels are predictive of disease progression among 65 patients with SMM. A receiver operating characteristic curve was used to establish a definition for high-risk baseline sBCMA. Mantel Byar analysis was used to examine whether high-risk sBCMA was correlated with shorter time to transformation, and a time-dependent cox proportional hazard was used to determine whether it is independent of other risk factors. A z test for proportions was used to compare the percentage of patients that progressed among high-risk versus low-risk sBCMA patients. A baseline sBCMA level ≥137.5 mg/ml was found to be the optimal cutoff between high- and low-risk SMM patients. Patients with high-risk sBCMA levels had a shorter time to transformation (P = .000332). sBCMA was also higher at the time of transformation than baseline levels (P = .0116). sBCMA was the only variable found to be significantly predictive of time to transformation and additionally was found to be independent of other risk factors. In this study, we have shown for the first time that sBCMA levels predict transformation of SMM to active disease and that these levels increase at the time of transformation. These results are consistent with other studies showing that active MM patients undergoing therapy with higher baseline sBCMA levels are more likely to progress early and its levels increase at the time of disease progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
European journal of haematology - 107(2021), 3 vom: 16. Sept., Seite 318-323 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bujarski, Sean [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2022 Date Revised 19.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.13666 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325448361 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325448361 | ||
| 003 | DE-627 | ||
| 005 | 20231225192447.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.13666 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325448361 | ||
| 035 | |a (NLM)33993536 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bujarski, Sean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2022 | ||
| 500 | |a Date Revised 19.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Multiple myeloma (MM) patients with smoldering (S) disease are defined by a lack of CRAB/SLiM criteria but may transform into disease requiring treatment. The International Myeloma Working Group risk stratification model for SMM uses serum M-protein, serum-free light chain ratio, and bone marrow plasma cell percentage. We investigated whether baseline serum B-cell maturation antigen (sBCMA) levels are predictive of disease progression among 65 patients with SMM. A receiver operating characteristic curve was used to establish a definition for high-risk baseline sBCMA. Mantel Byar analysis was used to examine whether high-risk sBCMA was correlated with shorter time to transformation, and a time-dependent cox proportional hazard was used to determine whether it is independent of other risk factors. A z test for proportions was used to compare the percentage of patients that progressed among high-risk versus low-risk sBCMA patients. A baseline sBCMA level ≥137.5 mg/ml was found to be the optimal cutoff between high- and low-risk SMM patients. Patients with high-risk sBCMA levels had a shorter time to transformation (P = .000332). sBCMA was also higher at the time of transformation than baseline levels (P = .0116). sBCMA was the only variable found to be significantly predictive of time to transformation and additionally was found to be independent of other risk factors. In this study, we have shown for the first time that sBCMA levels predict transformation of SMM to active disease and that these levels increase at the time of transformation. These results are consistent with other studies showing that active MM patients undergoing therapy with higher baseline sBCMA levels are more likely to progress early and its levels increase at the time of disease progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Smoldering Multiple Myeloma (SMM) | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a disease progression | |
| 650 | 4 | |a serum B-cell maturation antigen (sBCMA) | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Glycoproteins |2 NLM | |
| 650 | 7 | |a Immunoglobulin kappa-Chains |2 NLM | |
| 650 | 7 | |a Immunoglobulin lambda-Chains |2 NLM | |
| 650 | 7 | |a TNFRSF17 protein, human |2 NLM | |
| 650 | 7 | |a protein M (glycoprotein) |2 NLM | |
| 700 | 1 | |a Goldwater, Marissa-Skye |e verfasserin |4 aut | |
| 700 | 1 | |a Regidor, Bernard Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Jew, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Daniely, David |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Regina A |e verfasserin |4 aut | |
| 700 | 1 | |a Eades, Benjamin M |e verfasserin |4 aut | |
| 700 | 1 | |a Emamy-Sadr, Marsiye |e verfasserin |4 aut | |
| 700 | 1 | |a Souther, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Spektor, Tanya M |e verfasserin |4 aut | |
| 700 | 1 | |a Berenson, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 107(2021), 3 vom: 16. Sept., Seite 318-323 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2021 |g number:3 |g day:16 |g month:09 |g pages:318-323 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.13666 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2021 |e 3 |b 16 |c 09 |h 318-323 | ||